ABSTRACT
This evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR). The scope of this guideline includes prevention of Lyme disease, and the diagnosis and treatment of Lyme disease presenting as erythema migrans, Lyme disease complicated by neurologic, cardiac, and rheumatologic manifestations, Eurasian manifestations of Lyme disease, and Lyme disease complicated by coinfection with other tick-borne pathogens. This guideline does not include comprehensive recommendations for babesiosis and tick-borne rickettsial infections, which are published in separate guidelines. The target audience for this guideline includes primary care physicians and specialists caring for this condition such as infectious diseases specialists, emergency physicians, internists, pediatricians, family physicians, neurologists, rheumatologists, cardiologists and dermatologists in North America.
Subject(s)
Communicable Diseases , Lyme Disease , Neurology , Rheumatology , Animals , Humans , Lyme Disease/diagnosis , Lyme Disease/drug therapy , Lyme Disease/prevention & control , North America , United StatesABSTRACT
This evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR). The scope of this guideline includes prevention of Lyme disease, and the diagnosis and treatment of Lyme disease presenting as erythema migrans, Lyme disease complicated by neurologic, cardiac, and rheumatologic manifestations, Eurasian manifestations of Lyme disease, and Lyme disease complicated by coinfection with other tick-borne pathogens. This guideline does not include comprehensive recommendations for babesiosis and tick-borne rickettsial infections, which are published in separate guidelines. The target audience for this guideline includes primary care physicians and specialists caring for this condition such as infectious diseases specialists, emergency physicians, internists, pediatricians, family physicians, neurologists, rheumatologists, cardiologists and dermatologists in North America.
Subject(s)
Communicable Diseases , Lyme Disease , Neurology , Rheumatology , Animals , Humans , Lyme Disease/diagnosis , Lyme Disease/drug therapy , Lyme Disease/prevention & control , North America , United StatesABSTRACT
This evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR). The scope of this guideline includes prevention of Lyme disease, and the diagnosis and treatment of Lyme disease presenting as erythema migrans, Lyme disease complicated by neurologic, cardiac, and rheumatologic manifestations, Eurasian manifestations of Lyme disease, and Lyme disease complicated by coinfection with other tick-borne pathogens. This guideline does not include comprehensive recommendations for babesiosis and tick-borne rickettsial infections, which are published in separate guidelines. The target audience for this guideline includes primary care physicians and specialists caring for this condition such as infectious diseases specialists, emergency physicians, internists, pediatricians, family physicians, neurologists, rheumatologists, cardiologists and dermatologists in North America.
Subject(s)
Lyme Disease/diagnosis , Lyme Disease/therapy , Practice Guidelines as Topic/standards , Societies, Medical/standards , Humans , Lyme Disease/prevention & control , United StatesSubject(s)
Anti-Bacterial Agents/therapeutic use , Erythema Chronicum Migrans/drug therapy , Lyme Disease/drug therapy , Lyme Neuroborreliosis/drug therapy , Myocarditis/therapy , Tick Bites/diagnosis , Antibodies, Bacterial/blood , Antibodies, Bacterial/cerebrospinal fluid , Cardiac Pacing, Artificial , Duration of Therapy , Erythema Chronicum Migrans/diagnosis , Humans , Infectious Disease Medicine , Insect Repellents , Lyme Disease/diagnosis , Lyme Disease/prevention & control , Lyme Neuroborreliosis/diagnosis , Myocarditis/diagnosis , Myocarditis/physiopathology , Neurology , Rheumatology , Risk Assessment , Serologic Tests , Societies, MedicalABSTRACT
BACKGROUND: Antibiotic-impregnated bone cement spacer (ACS) with tobramycin ± vancomycin is commonly used in a 2-stage replacement of infected prosthetic joints. This procedure has been associated with development of acute kidney injury (AKI). OBJECTIVE: To determine the incidence and risk factors for AKI after implantation of tobramycin-impregnated ACS. METHODS: This prospective, observational study evaluated 50 consecutive patients who received tobramycin ACS for first-stage revision of an infected hip or knee arthroplasty from August 2011 to February 2013. AKI was defined as 50% or greater rise in serum creatinine (SCr) from baseline within the first 7 postoperative days (PODs). RESULTS: The incidence of AKI was 20%, with median onset occurring at POD 2 (interquartile range [IQR] = 1-3); patients with AKI had a longer median duration of hospital stay (16 days, IQR = 12-17, vs 10 days, IQR = 8-10; P = 0.03). Serum tobramycin concentrations were significantly higher in the AKI group, peaking on POD 1 (median 1.9 vs 0.9 µg/mL, P = 0.01). Risk factors for nephrotoxicity identified by multivariate analysis were use of bone cement premanufactured with gentamicin (OR = 8.2; 95% CI = 1.1-60; P = 0.04), administration of blood transfusions intraoperatively (OR = 32.5; 95% CI = 2.3-454.3; P = 0.01) and nonsteroidal anti-inflammatory drugs postoperatively (OR = 23.0; 95% CI = 1.3-397.7; P = 0.03). CONCLUSIONS: Tobramycin ACS is associated with a high risk of AKI. Measures to minimize AKI risk in the perioperative period include early detection through close monitoring of SCr, avoiding use of premanufactured bone cement containing gentamicin, and avoiding potential nephrotoxins within the first 72 hours postoperatively.
Subject(s)
Acute Kidney Injury/chemically induced , Anti-Bacterial Agents/adverse effects , Bone Cements , Surgical Wound Infection/chemically induced , Tobramycin/adverse effects , Acute Kidney Injury/epidemiology , Aged , Arthroplasty, Replacement, Hip , Arthroplasty, Replacement, Knee , Creatinine/blood , Female , Gentamicins/adverse effects , Humans , Incidence , Length of Stay , Male , Middle Aged , Perioperative Period , Prospective Studies , Reoperation , Risk Factors , Vancomycin/adverse effectsABSTRACT
BACKGROUND: Increasing multidrug resistance in gram-negative bacilli (GNB) infections poses a serious threat to public health. Few studies have analyzed co-resistance rates, defined as an antimicrobial susceptibility profile in a subset already resistant to one specific antibiotic. The epidemiologic and clinical utility of determining co-resistance rates are analyzed and discussed. METHODS: A 10-year retrospective study from 2002-2011 of bloodstream infections with GNB were analyzed from three hospitals in Greater Vancouver, BC, Canada. Descriptive statistics were calculated for antimicrobial resistance and co-resistance. Statistical analysis further described temporal trends of antimicrobial resistance, correlations of resistance between combinations of antimicrobials, and temporal trends in co-resistance patterns. RESULTS: The total number of unique blood stream isolates of GNB was 3280. Increasing resistance to individual antimicrobials was observed for E. coli, K. pneumoniae, K. oxytoca, E. cloacae, and P. aeruginosa. Ciprofloxacin resistance in E. coli peaked in 2006 at 40% and subsequently stabilized at 29% in 2011, corresponding to decreasing ciprofloxacin usage after 2007, as assessed by defined daily dose utilization data. High co-resistance rates were observed for ceftriaxone-resistant E. coli with ciprofloxacin (73%), ceftriaxone-resistant K. pneumoniae with trimethoprim-sulfamethoxazole (83%), ciprofloxacin-resistant E. cloacae with ticarcillin-clavulanate (91%), and piperacillin-tazobactam-resistant P. aeruginosa with ceftazidime (83%). CONCLUSIONS: Increasing antimicrobial resistance was demonstrated over the study period, which may partially be associated with antimicrobial consumption. The study of co-resistance rates in multidrug resistant GNB provides insight into the epidemiology of resistance acquisition, and may be used as a clinical tool to aid prescribing empiric antimicrobial therapy.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteremia/microbiology , Ciprofloxacin/pharmacology , Drug Resistance, Bacterial , Gram-Negative Bacterial Infections/microbiology , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/epidemiology , British Columbia/epidemiology , Ciprofloxacin/therapeutic use , Enterobacter cloacae/drug effects , Enterobacter cloacae/isolation & purification , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Humans , Klebsiella oxytoca/drug effects , Klebsiella oxytoca/isolation & purification , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Longitudinal Studies , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/isolation & purification , Retrospective Studies , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic useABSTRACT
OBJECTIVES: To determine whether utilization of moxifloxacin, a broad-spectrum fluoroquinolone antibiotic, has changed since its addition to the British Columbia provincial formulary in 2009 and to determine whether utilization was guideline concordant. METHODS: BC PharmaNet prescriptions for moxifloxacin from 2001 to 2010 were anonymously linked to associated Medical Services Plan fee-for-service practitioner claims for indication-specific analysis. Prescribing trends for adults ≥18 years of age were described using defined daily dose (DDD) per 1000 person-years. Monthly utilization rates were fit to a linear regression model that controlled for seasonal variation to examine the effect of the formulary addition. RESULTS: Utilization rose more than sevenfold throughout the study period, from 21.3 DDD per 1000 person-years in 2001 to 163.3 DDD per 1000 person-years in 2010. Although the formulary addition was not associated with an immediate increase in utilization (7.5% [95% CI -4.4% to 20.9%]; P=0.226), it was associated with an overall increase in utilization of 2.1% (95% CI 1.3% to 3.0%; P<0.001) for every month after 2009. Overall, only 29% of moxifloxacin prescriptions could be linked to a diagnostic code that was considered to be guideline concordant. In more than one-half of moxifloxacin prescriptions, the patient had not used another antibiotic in the previous 90 days. Among moxifloxacin prescriptions in which another antibiotic had been used in the previous 90 days, 41.5% were prescriptions for an alternative fluoroquinolone. CONCLUSIONS: The formulary addition was associated with a sustained increase in moxifloxacin utilization over time. Moxifloxacin is often prescribed to patients for indications that are not guideline concordant or to patients who have not previously received first-line antibiotics.
OBJECTIFS: Déterminer si l'utilisation de moxifloxacine, un antibiotique de la famille des fluoriquonolones à large spectre, a changé depuis son ajout au formulaire provincial de la Colombie-Britannique en 2009 et établir si cette utilisation concorde avec les lignes directrices. MÉTHODOLOGIE: Les chercheurs ont lié de manière anonyme les prescriptions de moxifloxacine figurant dans BC PharmaNet de 2001 à 2010 aux réclamations des médecins rémunérés à l'acte auprès du régime d'assurance-maladie connexe en vue d'une analyse propre aux indications. Ils ont décrit les tendances de prescription aux adultes de 18 ans ou plus au moyen de la dose quotidienne déterminée (DQD) sur 1 000 années-personne. Les taux d'utilisation mensuels respectaient un modèle de régression linéaire de variation saisonnière afin d'examiner l'effet de l'ajout au formulaire. RÉSULTATS: L'utilisation a plus que septuplé pendant la période de l'étude, passant de 21,3 DQD sur 1 000 années-personnes en 2001 à 163,3 DQD sur 1 000 années-personne en 2010. Même si l'ajout au formulaire ne s'associait pas à une augmentation immédiate de l'utilisation (7,5 % [95 % IC −4,4 % à 20,9 %]; P=0,226), il s'associait à une augmentation globale d'utilisation de 2,1 % (95 % IC 1,3 % à 3,0 %; P<0,001) chaque mois après 2009. Dans l'ensemble, seulement 29 % des prescriptions de moxifloxacine pouvaient être liées à un code diagnostique considéré comme correspondant à des lignes directrices. Dans plus de la moitié des prescriptions de moxifloxacine, le patient n'avait pas utilisé d'autre antibiotique au cours des 90 jours précédents. Parmi les prescriptions de moxifloxacine associées à l'utilisation d'un autre antibiotique au cours de 90 jours précédents, 41,5 % étaient des prescriptions pour une autre fluoroquinolone. CONCLUSIONS: L'ajout au formulaire s'est associé à une augmentation soutenue de l'utilisation de moxifloxacine au fil du temps. La moxifloxacine est souvent prescrite aux patients pour des indications qui ne correspondent pas aux lignes directrices ou à des patients qui n'ont pas reçu d'antibiotiques de première ligne auparavant.
ABSTRACT
UNLABELLED: WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Transrectal ultrasound guided prostate biopsies (TRUSBx) are associated with a spectrum of complications, including most significantly infection, which affects up to 5% of patients. In the most severe cases, infection leads to sepsis, a life-threatening complication. Escherichia coli is the primary responsible pathogen. Although antibiotic prophylaxis with fluoroquinolones is routinely used, there is evidence that the infection rate after TRUSBx is increasing, and this appears to be due to an increasing prevalence of ciprofloxacin-resistant rectal flora. This is the largest prospective clinical trial to date analysing the rectal flora of men undergoing prostate biopsies. We determined the microbial and antibiotic sensitivity profiles from 849 patients. Ciprofloxacin-resistant Gram-negative organisms were identified in the rectal flora of 19.0% of men. Furthermore, fluoroquinolone use within 6 months preceding a TRUSBx and the presence of a prosthetic heart valve were significant predictors of ciprofloxacin resistance on rectal swab. Determining the prevalence of rectal fluoroquinolone resistance has important implications in evaluation of the suitability of prophylactic regimens. Antimicrobial profiles derived from rectal swabs pre-biopsy may prove useful in guiding targeted antibiotic prophylaxis. OBJECTIVES: To establish the prevalence of ciprofloxacin-resistant bacteria in patients undergoing transrectal ultrasound guided prostate biopsies (TRUSBx) and to determine whether this predicts subsequent infectious complications. To identify risk factors for harbouring ciprofloxacin-resistant flora. PATIENTS AND METHODS: Any patient undergoing a TRUSBx from 2009 to 2011 was eligible for enrolment in this prospective study. Pre-biopsy rectal and urine cultures and post-biopsy urine cultures were obtained and antimicrobial susceptibility was determined. Univariate and multivariate analyses were performed to identify independent patient risk factors associated with ciprofloxacin-resistant rectal flora. RESULTS: A total of 865 patients underwent TRUSBx, of whom 19.0% were found to have ciprofloxacin-resistant Gram-negative coliforms. Escherichia coli was the most prevalent Gram-negative rectal isolate (80.9%) and accounted for 90.6% of ciprofloxacin resistance. Patient characteristics that conferred an increased risk of harbouring ciprofloxacin-resistant organisms included a history of a heart valve replacement (P < 0.05) and ciprofloxacin use in the past 3 months (P < 0.05). Infectious complications were observed in 3.6% (n = 31) of the patient population and 48% of these patients grew ciprofloxacin-resistant organisms on the pre-biopsy rectal swab (P < 0.001). CONCLUSIONS: Antimicrobial resistance to ciprofloxacin in the rectal flora was common, particularly in patients with recent ciprofloxacin use and a heart valve replacement. Despite a significant correlation between those patients who developed infections and the detection of ciprofloxacin-resistant organisms, only 9.0% (n = 15) of the total group with ciprofloxacin resistance developed an infectious complication. Future studies will need to evaluate the cost effectiveness and clinical utility of a pre-biopsy rectal culture in targeting antibiotic prophylaxis.
Subject(s)
Anti-Infective Agents, Urinary/therapeutic use , Antibiotic Prophylaxis/methods , Ciprofloxacin/therapeutic use , Drug Resistance, Bacterial , Endoscopic Ultrasound-Guided Fine Needle Aspiration/adverse effects , Escherichia coli Infections/prevention & control , Escherichia coli/isolation & purification , Feces/microbiology , Prostatic Neoplasms/pathology , Rectum/microbiology , Adult , Aged , Aged, 80 and over , Analysis of Variance , Anti-Infective Agents, Urinary/administration & dosage , Canada/epidemiology , Ciprofloxacin/administration & dosage , Escherichia coli Infections/epidemiology , Humans , Male , Middle Aged , Prevalence , Prospective Studies , Prostatic Neoplasms/diagnostic imaging , Rectum/pathology , Treatment OutcomeABSTRACT
PURPOSE: Transrectal ultrasound guided prostate biopsy can lead to urinary tract infections in 3% to 11% and sepsis in 0.1% to 5% of patients. We investigated the efficacy of rectal cleansing with povidone-iodine before transrectal ultrasound guided prostate biopsy to reduce infectious complications. MATERIALS AND METHODS: Between 2009 and 2011, 865 men were prospectively randomized to rectal cleansing (421) or no cleansing (444) before transrectal ultrasound guided prostate biopsy. Patients received ciprofloxacin prophylaxis and rectal swab cultures were obtained before transrectal ultrasound guided prostate biopsy. Patients completed a telephone interview 7 days after undergoing the biopsy. The primary end point was the rate of infectious complications, a composite end point of 1 or more of 1) fever greater than 38.0C, 2) urinary tract infection or 3) sepsis (standardized definition). Chi-square significance testing was performed for differences between groups and a multivariate analysis was performed to assess risk factors for infectious complications. RESULTS: Infectious complications were observed in 31 (3.5%) patients, including 11 (2.6%) treated and 20 (4.5%) control patients (p = 0.15). Sepsis was observed in 4 (1.0%) treated and 7 (1.6%) control patients (p = 0.55). On multivariate analysis resistance to ciprofloxacin in the rectal swab culture (p = 0.002) and a history of taking ciprofloxacin in the 3 months preceding transrectal ultrasound guided prostate biopsy (p = 0.009) predicted infectious complications. CONCLUSIONS: Rectal cleansing with povidone-iodine before transrectal ultrasound guided prostate biopsy was safe, but the 42% relative risk reduction of infectious complications was not statistically significant. Patients who have received ciprofloxacin within 3 months of transrectal ultrasound guided prostate biopsy should be considered for alternate prophylaxis or possibly a delay of biopsy beyond 3 months.
Subject(s)
Anti-Infective Agents, Local/therapeutic use , Bacterial Infections/prevention & control , Image-Guided Biopsy/adverse effects , Povidone-Iodine/therapeutic use , Preoperative Care/methods , Prostate/pathology , Aged , Humans , Male , Middle Aged , Prospective Studies , Prostate/diagnostic imaging , Rectum , Ultrasonography, InterventionalABSTRACT
This study examined the distribution of antibiotic resistant Escherichia coli and E. coli O157 isolated from water, sediment and biofilms in an intensive agricultural watershed (Elk Creek, British Columbia) between 2005 and 2007. It also examined physical and chemical water parameters associated with antibiotic resistance. Broth microdilution techniques were used to determine minimum inhibitory concentrations (MIC) for E. coli (n=214) and E. coli O157 (n=27) recovered isolates for ampicillin, cefotaxime, ciprofloxacin, nalidixic acid, streptomycin and tetracycline. Both E. coli and E. coli O157 isolates showed highest frequency of resistance to tetracycline, ampicillin, streptomycin and nalidixic acid; respectively. For E. coli, the highest frequency of resistance was observed at the most agriculturally-impacted site, while the lowest frequency of resistance was found at the headwaters. Sediment and river rock biofilms were the most likely to be associated with resistant E. coli, while water was the least likely. While seasonality (wet versus dry) had no relationship with resistance frequency, length of biofilm colonization of the substratum in the aquatic environment only affected resistance frequency to nalidixic acid and tetracycline. Multivariate logistic regressions showed that water depth, nutrient concentrations, temperature, dissolved oxygen and salinity had statistically significant associations with frequency of E. coli resistance to nalidixic acid, streptomycin, ampicillin and tetracycline. The results indicate that antibiotic resistant E. coli and E. coli O157 were prevalent in an agricultural stream. Since E. coli is adept at horizontal gene transfer and prevalent in biofilms and sediment, where ample opportunities for genetic exchange with potential environmental pathogens present themselves, resistant isolates may present a risk to ecosystem, wildlife and public health.
Subject(s)
Agriculture , Biofilms , Drug Resistance, Microbial , Escherichia coli/isolation & purification , Geologic Sediments/microbiology , Water Microbiology , British Columbia , Escherichia coli/drug effects , Microbial Sensitivity TestsABSTRACT
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has spread rapidly throughout the world in the last decade. We sought to demonstrate the impact of the emergence of CA-MRSA in Western Canada on physician visits, incision-and-drainage procedures, and antibiotic prescribing for skin and soft tissue infections (SSTI). We used the provincial physician billing system to determine the rate of physician visits (per 1,000 population per year) of SSTI and incision-and-drainage procedures. A database capturing all outpatient prescriptions in the province was anonymously linked to associated physician billing codes to quantify prescriptions associated with SSTI. Antibiotic prescriptions (overall and class specific) were expressed as their defined daily dose (DDD) per 1,000 inhabitants per day. Between 1996 and 2008, the rate of visits for all SSTI increased by 15%, and the majority of visits did not include an incision-and-drainage procedure. The rate of antibiotic prescribing for SSTI increased by 49%. The majority of this increase was attributable to the higher rates of use of clindamycin (627%), trimethoprim-sulfamethoxazole (380%), cephalosporins (160%), and amoxicillin-clavulanate (627%). Health care utilization and antibiotic prescribing rates for SSTI, but not incision-and-drainage procedures, have increased in association with the CA-MRSA epidemic. While much of the increase in antibiotic use reflects an appropriate change to trimethoprim-sulfamethoxazole, there is room for education regarding the limitations of cephalosporins and clindamycin, given current susceptibility profiles.
Subject(s)
Anti-Bacterial Agents/adverse effects , Drug Utilization/trends , Skin Diseases, Infectious/epidemiology , Soft Tissue Infections/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , British Columbia/epidemiology , Databases, Factual , Drug Utilization/statistics & numerical data , Female , Humans , Male , Middle Aged , Office Visits/statistics & numerical data , Population , Skin Diseases, Infectious/drug therapy , Skin Diseases, Infectious/surgery , Soft Tissue Infections/drug therapy , Soft Tissue Infections/surgery , Young AdultABSTRACT
Despite its relevance to public health, presence and concentrations of Campylobacter spp. in biofilms in natural aquatic environments has not been investigated. This study examined the occurrence of Campylobacter spp. in biofilms on a variety of surfaces (river rock, slate rock, wood, Lexan™, sandpaper, and sediment) and in water from December 2005 to December 2006 to find a substratum that facilitated campylobacters detection in natural aquatic environments. Samples were collected at four sites in an agricultural watershed (Elk Creek, British Columbia). Campylobacter spp. presence was determined using culturing methods. Correlations between chemical, physical and microbiological water quality parameters and Campylobacter spp. distribution on different surface types were also investigated. Campylobacter spp. had a prevalence of 13% in the wet season, but was not recovered in the dry season. Its prevalence was highest in sediment (27%), followed by slate rock (22%), Lexan and wood (13%), river rock (9%) and water (8%), respectively. No Campylobacter spp. was found in sandpaper biofilms. Several other criteria were used to assess substrata effectiveness, such as correlation amongst Campylobacter spp., indicator bacteria and water quality parameters, cost and availability of substratum, potential for standardizing substratum, ease of biofilm removal and probability of substratum loss in situ. Results show that sediment, slate rock or wood could be used as substrata for Campylobacter spp. monitoring. The study also highlights the potential use of nitrates and enterococci as faecal contamination indicators to protect public health.
Subject(s)
Biofilms , Campylobacter/isolation & purification , Environmental Monitoring , Water Quality , British Columbia , Campylobacter/physiology , Geologic Sediments/microbiology , Surface Properties , Water Microbiology , Water SupplyABSTRACT
BACKGROUND: The Sustainably Managing Environmental Health Risk in Ecuador project was launched in 2004 as a partnership linking a large Canadian university with leading Cuban and Mexican institutes to strengthen the capacities of four Ecuadorian universities for leading community-based learning and research in areas as diverse as pesticide poisoning, dengue control, water and sanitation, and disaster preparedness. METHODS: In implementing curriculum and complementary innovations through application of an ecosystem approach to health, our interdisciplinary international team focused on the question: "Can strengthening of institutional capacities to support a community of practice of researchers, practitioners, policy-makers and communities produce positive health outcomes and improved capacities to sustainably translate knowledge?" To assess progress in achieving desired outcomes, we review results associated with the logic framework analysis used to guide the project, focusing on how a community of practice network has strengthened implementation, including follow-up tracking of program trainees and presentation of two specific case studies. RESULTS: By 2009, train-the-trainer project initiation involved 27 participatory action research Master's theses in 15 communities where 1200 community learners participated in the implementation of associated interventions. This led to establishment of innovative Ecuadorian-led master's and doctoral programs, and a Population Health Observatory on Collective Health, Environment and Society for the Andean region based at the Universidad Andina Simon Bolivar. Building on this network, numerous initiatives were begun, such as an internationally funded research project to strengthen dengue control in the coastal community of Machala, and establishment of a local community eco-health centre focusing on determinants of health near Cuenca. DISCUSSION: Strengthening capabilities for producing and applying knowledge through direct engagement with affected populations and decision-makers provides a fertile basis for consolidating capacities to act on a larger scale. This can facilitate the capturing of benefits from the "top down" (in consolidating institutional commitments) and the "bottom up" (to achieve local results). CONCLUSIONS: Alliances of academic and non-academic partners from the South and North provide a promising orientation for learning together about ways of addressing negative trends of development. Assessing the impacts and sustainability of such processes, however, requires longer term monitoring of results and related challenges.
ABSTRACT
Objetivo. Recopilar datos iniciales sobre las enfermedades infecciosas y el uso deantibióticos en dos comunidades indígenas andinas del Ecuador, con el objeto de determinar la factibilidad y la aceptabilidad de aplicar un enfoque ecosistémico para abordar los problemas asociados.Métodos. Mediante visitas a 65 hogares con niños menores de 5 años, se valoraron los factores de riesgo ambientales de las enfermedades infecciosas mediante una evaluación rápida. Se identificaron los conocimientos, las actitudes y las prácticas de los cuidadores relacionados con el uso de antibióticos por medio de una encuesta de conocimientos, prácticas y cobertura; el uso de antibióticos se dedujo a partir de lainspección de los botiquines; y se evaluó el estado general de salud de los 91 niños (incluido su estado de nutrición). Se organizó un taller para transmitir los resultadosy para diseñar una intervención de múltiples componentes basada en un marco ecosistémico de la salud. Resultados. Se encontraron numerosos factores de riesgo ambientales, especialmentelos relacionados con el agua y el saneamiento. El análisis del conocimiento, las actitudes y las prácticas reveló el uso de medicamentos tradicionales y occidentales, y profundas brechas de conocimiento. Había antibióticos en 60,9% de los hogares de Correuco y en 46,8% de La Posta; las tasas de desnutrición eran de 22,2% en Correuco y de 26,1% en La Posta; el mes anterior a la encuesta 26,7% de los niños de Correuco y 47,8% de los niños de La Posta habían tenido episodios de diarrea, con prescripción de antibióticos en 50,0% y 47,1% de los casos, respectivamente; y 28,9% de los niños de Correuco y 47,8% de los niños de La Posta habían tenido infecciones respiratorias agudas, con prescripción de antibióticos en 53,8% y 50,0% de los casos, respectivamente...
Objective. To collect baseline data on infectious diseases and antibiotic use in two Andean indigenous communities in Ecuador in order to determine the feasibility and acceptability of applying an ecosystem approach to address associated problems. Methods. In visits to 65 households with children under age 5 years, environmental risk factors for infectious diseases were evaluated through rapid assessment. Caregiversknowledge, attitudes, and practices related to antibiotic use were determined through a knowledge, practices, and coverage survey; antibiotic use was gleaned from inspection of medicine chests; and overall health of the 91 children (including nutritional status) wasassessed. A workshop was held to share results and to craft a multicomponent intervention using an ecohealth framework. Results. Numerous environmental risk factors were identified, especially related to waterand sanitation. Knowledge, attitudes, and practices revealed use of traditional and Western medicines and serious knowledge gaps. Antibiotics were present in 60.9% of households inCorreuco and 46.8% in La Posta; malnutrition rates were 22.2% in Correuco and 26.1% in La Posta; diarrheic episodes were experienced in the previous month by 26.7% of children in Correuco and 47.8% in La Posta, with antibiotics prescribed in 50.0% and 47.1% of cases, respectively; and acute respiratory infections were incurred by 28.9% of children in Correuco and 47.8% in La Posta, with antibiotics prescribed in 53.8% and 50.0% of cases, respectively. Conclusions. Environmental, social, and cultural factors must be addressed to preventantibiotic resistance in addition to training health personnel. An ecosystem approach is wellsuited for this goal.
Subject(s)
Child, Preschool , Humans , Infant , Anti-Bacterial Agents/therapeutic use , Child Welfare , Drug Resistance, Microbial , Ecosystem , Inappropriate Prescribing/prevention & control , Population Groups , Rural Health , Anthropometry , Canada , Caregivers/psychology , Culture , Drug Utilization/statistics & numerical data , Ecuador/epidemiology , Family Characteristics , Health Knowledge, Attitudes, Practice , Housing/statistics & numerical data , Hygiene , International Cooperation , Malnutrition/ethnology , Pilot Projects , Population Groups/statistics & numerical data , Risk FactorsABSTRACT
OBJECTIVE: To collect baseline data on infectious diseases and antibiotic use in two Andean indigenous communities in Ecuador in order to determine the feasibility and acceptability of applying an ecosystem approach to address associated problems. METHODS: In visits to 65 households with children under age 5 years, environmental risk factors for infectious diseases were evaluated through rapid assessment. Caregivers' knowledge, attitudes, and practices related to antibiotic use were determined through a knowledge, practices, and coverage survey; antibiotic use was gleaned from inspection of medicine chests; and overall health of the 91 children (including nutritional status) was assessed. A workshop was held to share results and to craft a multicomponent intervention using an ecohealth framework. RESULTS: Numerous environmental risk factors were identified, especially related to water and sanitation. Knowledge, attitudes, and practices revealed use of traditional and Western medicines and serious knowledge gaps. Antibiotics were present in 60.9% of households in Correuco and 46.8% in La Posta; malnutrition rates were 22.2% in Correuco and 26.1% in La Posta; diarrheic episodes were experienced in the previous month by 26.7% of children in Correuco and 47.8% in La Posta, with antibiotics prescribed in 50.0% and 47.1% of cases, respectively; and acute respiratory infections were incurred by 28.9% of children in Correuco and 47.8% in La Posta, with antibiotics prescribed in 53.8% and 50.0% of cases, respectively. CONCLUSIONS: Environmental, social, and cultural factors must be addressed to prevent antibiotic resistance in addition to training health personnel. An ecosystem approach is well-suited for this goal.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Child Welfare , Drug Resistance, Microbial , Ecosystem , Inappropriate Prescribing/prevention & control , Population Groups , Rural Health , Anthropometry , Canada , Caregivers/psychology , Child, Preschool , Culture , Drug Utilization/statistics & numerical data , Ecuador/epidemiology , Family Characteristics , Health Knowledge, Attitudes, Practice , Housing/statistics & numerical data , Humans , Hygiene , Infant , International Cooperation , Malnutrition/ethnology , Pilot Projects , Population Groups/statistics & numerical data , Risk FactorsSubject(s)
Drug Resistance, Microbial , Anti-Bacterial Agents , Drug Prescriptions , Indigenous Peoples , Child, Preschool , Ecuador , Drug Resistance, Microbial , Anti-Bacterial Agents , Drug Prescriptions , Indigenous Peoples , Child, Preschool , Anti-Bacterial Agents , Child Health , Drug Resistance, Microbial , Ecosystem , Population Groups , Anthropometry , Canada , Caregivers , Culture , Drug Utilization , Hygiene , Pilot Projects , Inappropriate Prescribing , Rural Health , Family Characteristics , Health Knowledge, Attitudes, Practice , Housing , International Cooperation , Malnutrition , Risk FactorsABSTRACT
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging pathogen first described among individuals with no contact with health care facilities. The purpose of this study was to determine the proportion of CA-MRSA, defined by pulsed field gel electrophoresis (PFGE), in MRSA skin and soft tissue infections presenting to the Emergency Department (ED). We also aimed to describe the laboratory and clinical characteristics of CA-MRSA infections. From June 1, 2001 to May 30, 2005, MRSA isolates from skin and soft tissue infections presenting to the ED were reviewed. They were characterized by antibiotic susceptibilities and PFGE, and the presence of staphylococcal cassette chromosome (SCC) mec type IVa and Panton-Valentine leukocidin (PVL) genes was assessed on representative isolates. The medical records were reviewed to define risk factors. There were 95 isolates available for analysis, of which 58 (61%) were CMRSA-10 (USA-300), the predominant clone from 2003 onward. All representative isolates (24%) tested in this group had PVL genes and SCCmec type IVa. Their antibiogram showed 100% susceptibility to trimethoprim-sulfamethoxazole, rifampin, and fusidic acid, and 79% to clindamycin. Clinical comparison of CMRSA-10 vs. hospital PFGE type strains showed 22% vs. 60%, respectively, for recent antibiotic use (p < 0.0001), 26% vs. 6%, respectively, for intravenous drug use (p < 0.05), and 57% vs. 6%, respectively, for soft tissue abscess (p < 0.001). CMRSA-10 is a major pathogen in skin and soft tissue abscesses in our ED. It has a characteristic susceptibility, and was associated with intravenous drug use, but not with recent antibiotic usage.
Subject(s)
Community-Acquired Infections/microbiology , Methicillin-Resistant Staphylococcus aureus/classification , Skin Diseases, Infectious/microbiology , Soft Tissue Infections/microbiology , Staphylococcal Infections/microbiology , Adult , Bacterial Toxins/genetics , British Columbia/epidemiology , Community-Acquired Infections/epidemiology , Drug Resistance, Bacterial , Emergency Service, Hospital/statistics & numerical data , Exotoxins/genetics , Female , Humans , Leukocidins/genetics , Male , Methicillin-Resistant Staphylococcus aureus/genetics , Retrospective Studies , Risk Factors , Skin Diseases, Infectious/epidemiology , Soft Tissue Infections/epidemiology , Staphylococcal Infections/epidemiology , Substance Abuse, Intravenous/microbiologyABSTRACT
BACKGROUND: Antibiotic exposure in early childhood is a possible contributor to the increasing asthma prevalence in industrialized countries. Although a number of published studies have tested this hypothesis, the results have been conflicting. OBJECTIVE: To explore the association between antibiotic exposure before 1 year of age and development of childhood asthma. METHODS: Using administrative data, birth cohorts from 1997 to 2003 were evaluated (N = 251817). Antibiotic exposure was determined for the first year of life. After the first 24 months of life, the incidence of asthma was determined in both those exposed and not exposed to antibiotics in the first 12 months of life. Cox proportional hazards models were used to adjust for potential confounders and determine the hazard ratios associated with antibiotic exposure for the development of asthma. RESULTS: Antibiotic exposure in the first year of life was associated with a small risk of developing asthma in early childhood after adjusting for gender, socioeconomic status at birth, urban or rural address at birth, birth weight, gestational age, delivery method, frequency of physician visits, hospital visit involving surgery, visits to an allergist, respirologist, or immunologist, congenital anomalies, and presence of otitis media, acute, or chronic bronchitis, and upper and lower respiratory tract infections during the first year of life. As the number of courses of antibiotics increased, this was associated with increased asthma risk, with the highest risk being in children who received >4 courses. All antibiotics were associated with an increased risk of developing asthma, with the exception of sulfonamides. CONCLUSIONS: This study provides evidence that the use of antibiotics in the first year of life is associated with a small risk of developing asthma, and this risk increases with the number of courses of antibiotics prescribed.
